Vancomycin in Combination with Other Antibiotics for the Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections

被引:114
作者
Deresinski, Stan [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
[2] Santa Clara Valley Med Ctr, Div Infect Dis, San Jose, CA 95128 USA
关键词
IN-VITRO ACTIVITY; PLUS RIFAMPIN; BETA-LACTAMS; QUINUPRISTIN-DALFOPRISTIN; EXPERIMENTAL ENDOCARDITIS; BACTERICIDAL ACTIVITIES; ANTIMICROBIAL THERAPY; VALVE ENDOCARDITIS; EMPIRICAL-THERAPY; STANDARD THERAPY;
D O I
10.1086/605572
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vancomycin is often combined with a second antibiotic, most often rifampin or gentamicin, for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Published data from experiments evaluating these and other vancomycin-based combinations, both in vitro and in animal models of infection, often yield inconsistent results, however. More importantly, no data are available from randomized clinical trials to support their use, and some regimens are known to have potential toxicities. Clinicians should carefully reconsider the use of vancomycin-based combination therapies for the treatment of infection due to methicillin-resistant S. aureus.
引用
收藏
页码:1072 / 1079
页数:8
相关论文
共 94 条
[1]   Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus [J].
Adhikari, RP ;
Scales, GC ;
Kobayashi, K ;
Smith, JMB ;
Berger-Bächi, B ;
Cook, GM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :360-363
[2]   Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model [J].
Aeschlimann, JR ;
Allen, GP ;
Hershberger, E ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :2991-2998
[3]   Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis -: art. no. 43 [J].
Alp, E ;
Gozukucuk, S ;
Canoz, O ;
Kirmaci, B ;
Doganay, M .
BMC INFECTIOUS DISEASES, 2004, 4 (1)
[4]   Combination therapy with daptomycin, vancomycin, and rifampin for recurrent, severe bone and prosthetic joint infections involving methicillin-resistant Staphylococcus aureus [J].
Antony, Suresh J. .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (04) :293-295
[5]  
Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
[6]   In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus [J].
Bahl, D ;
Miller, DA ;
Leviton, I ;
Gialanella, P ;
Wolin, MJ ;
Liu, WG ;
Perkins, R ;
Miller, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1293-1297
[7]   Initial Low-Dose Aminoglycosides in Staphylococcus aureus Bacteremia: Good Science, Urban Legend, or Just Plain Toxic? [J].
Bayer, Arnold S. ;
Murray, Barbara E. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (06) :722-724
[8]   DISPARITY BETWEEN TIMED-KILL AND CHECKERBOARD METHODS FOR DETERMINATION OF INVITRO BACTERICIDAL INTERACTIONS OF VANCOMYCIN PLUS RIFAMPIN VERSUS METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS [J].
BAYER, AS ;
MORRISON, JO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (02) :220-223
[9]   EFFICACY OF VANCOMYCIN PLUS RIFAMPIN IN EXPERIMENTAL AORTIC-VALVE ENDOCARDITIS DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS-AUREUS - INVITRO INVIVO CORRELATIONS [J].
BAYER, AS ;
LAM, K .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (01) :157-165
[10]   Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus [J].
Bennett, Jason W. ;
Murray, Clinton K. ;
Holmes, Robert L. ;
Patterson, Jan E. ;
Jorgensen, James H. .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 60 (04) :437-440